Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | NPC1 | O15118 | 9/20 | 0.64 |
| ▸ | RAB9A | P51151 | 8/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.59 |
| ▸ | RELA | Q04206 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8267163 | 0.91 | SMN1; SMN2 (0.88) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL10192041 | 0.87 | SMN1; SMN2 (0.76) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL8266868 | 0.84 | RAB9A (0.77) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL24025328 | 0.84 | NPC1 (0.67) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL8267150 | 0.84 | NPC1 (0.67) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL11534377 | 0.84 | SMN1; SMN2 (0.77) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL8267156 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL8267152 | 0.83 | NPC1 (0.79) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL8267173 | 0.82 | NPC1 (0.90) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A | |
| SCHEMBL24025347 | 0.82 | MAPT (0.61) | SMN1; SMN2ALDH1A1USP2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210355093-A1 | NOVEL COMPOUND AND APPLICATION THEREOF IN TREATING INFLAMMATION OR INFLAMMATION-RELATED DISEASES | SICHUAN CENTER FOR TRANSLATIONAL MEDICINE OF TRADITIONAL CHINESE MEDICINE (CN) | 2021-11-18 | — | — | US | disclosed |
| US-7291743-B2 | Isoxazole derivatives and methods of treating nitric oxide mediated diseases | GENEBLUE CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291743-B2 | Isoxazole derivatives and methods of treating nitric oxide mediated diseases | GENEBLUE CORPORATION (US) | 2007-11-06 | — | — | US | disclosed |
| US-20060223873-A1 | Isoxazole derivatives and methods of treating nitric oxide mediated diseases | GENEBLUE CORPORATION | 2006-10-05 | — | — | US | disclosed |
| US-20060223873-A1 | Isoxazole derivatives and methods of treating nitric oxide mediated diseases | GENEBLUE CORPORATION | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223873-A1 | Isoxazole derivatives and methods of treating nitric oxide mediated diseases | NOS1, NOS2, NOS3 | SMN1; SMN2 3623/4885ALDH1A1 295/4885USP2 3219/4885 |
| US-20210355093-A1 | NOVEL COMPOUND AND APPLICATION THEREOF IN TREATING INFLAMMATION OR INFLAMMATION-RELATED DISEASES | PTGES2, PTGS1, PTGS2 | SMN1; SMN2 4290/4885ALDH1A1 2283/4885USP2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.